An aged patient with stage IV ovarian cancer successfully treated by intraperitoneal consecutive administration of cisplatin

• Published in: Gan to kagaku ryoho Vol. 25; no. 8; p. 1225
• Main Authors: Narimatsu, A, Okada, O
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.07.1998
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cisplatin - administration & dosage; Cyclophosphamide - administration & dosage; Cystadenocarcinoma, Papillary - drug therapy; Cystadenocarcinoma, Papillary - secondary; Drug Administration Schedule; Female; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Infusions, Parenteral; Lymphatic Metastasis; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology
• ISSN: 0385-0684

The patient was an aged woman with ovarian cancer stage IV that was classified as serous papillary adenocarcinoma. The primary lesion, 60 x 70 x 100 mm in size, was detected in the left ovary and the lymph node metastasis, 54 x 35 mm in the maximum size, expanded from the pelvic lymph node to the left supraclavicular lymph node. The patient underwent three courses of chemotherapy at intervals of three weeks. Cisplatin was intraperitoneally administered in a divided dose of 20 mg from day 1 to day 4, and cyclophosphamide was intravenously infused in a dose of 500 mg on day 1. As a result, histological efficacies of Grade III were recognized not only in the primary lesion but also in the metastatic lesions including lymph nodes. No adverse effects were observed, and the free Pt AUC in cubital blood measured after a course of chemotherapy (3.0 mg.hr/l) was higher than that measured after 2 hour-drip infusion of cisplatin 100 mg/day. The concentration of free Pt in ascites measured one hour after intraperitoneal administration was 2.8 micrograms/ml. These findings show that this method is a highly effective therapy with few adverse effects. In view of these advantages, this therapeutic technique should be considered as first-line chemotherapy for aged patients and those with serous adenocarcinoma who prefer in-home treatment.